Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session
March 17, 2019 15:00 ET
|
PhaseBio Pharmaceuticals, Inc.
PB2452 achieved immediate and sustained reversal of ticagrelor antiplatelet effects Results support continued development of PB2452 as ticagrelor reversal agent MALVERN, Penn. and SAN DIEGO, March ...
PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference
March 06, 2019 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Appoints Richard A. van den Broek to Board of Directors
March 04, 2019 08:30 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., and SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiology’s 68th Annual Scientific Session
March 04, 2019 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., and SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Appoints Edmund P. Harrigan to Board of Directors
December 17, 2018 16:30 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Reports Third Quarter 2018 Financial and Business Results
November 29, 2018 16:30 ET
|
PhaseBio Pharmaceuticals, Inc.
Closed initial public offering that raised $43.0 million in net proceeds Demonstrated proof of concept for PB2452, supporting continued development for the reversal of antiplatelet activity of...
PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension
November 27, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio To Report Third Quarter 2018 Financial and Business Results on November 29, 2018
November 21, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio to Present at Stifel 2018 Healthcare Conference
November 07, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
PhaseBio Announces Pricing of Initial Public Offering
October 17, 2018 19:24 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Oct. 17, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (“PhaseBio”), a clinical-stage biopharmaceutical company focused on the development and commercialization...